Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabidiol (Specific Conjugate Particles)
- Development stage
- Preclinical
- Lead developer
- Nexus Alliance Biopharma
- Modality
- Small Molecules
- Administration
- Oral, Inhalation, Sublingual, Oromucosal, Topical, Dermal, Transdermal, Rectal, Intravenous, Intramuscular, Subcutaneous, Intraperitoneal, Intranasal, Buccal, Mucosal
01
Overview
Cannabidiol (Specific Conjugate Particles), or SCP-CBD, is a formulation of cannabidiol (CBD) utilizing Specific Conjugate Particles (SCP) technology. Cannabidiol is a non-psychoactive phytocannabinoid derived from Cannabis sativa, known for its complex and multi-targeted mechanism of action. It indirectly modulates the endocannabinoid system by inhibiting the breakdown of anandamide, thereby increasing its levels. CBD also interacts with various non-cannabinoid receptors, including 5-HT1A (serotonin) receptors, TRPV1/2 (transient receptor potential vanilloid) channels, GPR55, and PPAR-γ (peroxisome proliferator-activated receptor gamma). Additionally, it acts as an allosteric modulator of GABAA receptors, activates neuronal Kv7 potassium channels, and influences several cytochrome P450 enzymes. This broad pharmacological profile contributes to its potential therapeutic effects, which include anti-inflammatory, anxiolytic, neuroprotective, and anticonvulsant properties. The SCP technology aims to enhance the delivery and efficacy of cannabis extracts, including CBD, for various applications.
- Other names
- SCP-CBD
02
Targets
CYP2C19 (Cytochrome P450 2C19)PPARG (Peroxisome proliferator-activated receptor gamma)CYP1A2 (Cytochrome P450 1A2)CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)ADRA1A (α1A)TRPV2 (Transient receptor potential cation channel subfamily V member 2)MOR (Mu opioid receptor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)GPR55 (G protein-coupled receptor 55)KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))CYP2B6 (Cytochrome P450 2B6)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)FAAHCYP2C8 (Cytochrome P450 2C8)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on Cannabidiol (Specific Conjugate Particles).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cannabidiol (Specific Conjugate Particles).